<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Glomerular diseases due to nonamyloid fibrillar deposits</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Glomerular diseases due to nonamyloid fibrillar deposits</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Glomerular diseases due to nonamyloid fibrillar deposits</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Fernando C Fervenza, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sanjeev Sethi, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard J Glassock, MD, MACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Brad H Rovin, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 23, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Glomerular disease may be associated with the appearance of fibrillar deposits in the mesangium or glomerular basement membrane. The fibrils are Congo red positive in <strong>amyloidosis</strong> and are typically Congo red negative in other forms. The most common forms of nonamyloid fibrillary glomerular deposition diseases are <strong>fibrillary glomerulonephritis</strong> and <strong>immunotactoid glomerulopathy</strong>.</p><p>Fibrillary glomerulonephritis [<a href="#rid1">1-7</a>] and immunotactoid glomerulopathy [<a href="#rid3">3,5,6,8-10</a>] are uncommon, but distinctly different, causes of glomerular disease. Both disorders result from deposits derived from immunoglobulins [<a href="#rid10">10</a>]. Other forms of nonamyloid fibrillary deposition disease have been described in which the deposits are composed of fibronectin (fibronectin glomerulopathy) or atypical type III collagen fibrils (collagenofibrotic glomerulopathy). (See <a class="local">'Pathology and pathogenesis'</a> below and <a class="local">'Other fibrillary disorders'</a> below.)</p><p>Glomerular disease associated with amyloid deposits is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3120.html" rel="external">"Renal amyloidosis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">FIBRILLARY AND IMMUNOTACTOID DISEASE</span><span class="headingEndMark"> — </span>Fibrillary glomerulonephritis and immunotactoid glomerulopathy are uncommon disorders, being present in 0.5 to 1.4 percent of native kidney biopsies [<a href="#rid3">3,6</a>]. They are separate disorders [<a href="#rid2">2,3,9,11,12</a>], with fibrillary glomerulonephritis accounting for approximately 85 to 90 percent of cases [<a href="#rid3">3,5,9</a>]. The identification of the protein DnaJ heat shock protein family (Hsp40) member B9 (DNAJB9) in the glomeruli of patients with fibrillary glomerulonephritis but not in those with immunotactoid glomerulopathy [<a href="#rid13">13-15</a>] has made it clear that the two are distinct, pathogenically unrelated disease entities. (See <a class="local">'Fibrillary glomerulonephritis'</a> below.)</p><p class="headingAnchor" id="H3526196199"><span class="h2">Pathology and pathogenesis</span></p><p class="headingAnchor" id="H3779425517"><span class="h3">Fibrillary glomerulonephritis</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathology</strong> – The diagnosis of fibrillary glomerulonephritis is established by kidney biopsy, with the pathognomonic changes seen on electron microscopy and with immunofluorescence or immunohistochemical staining for DNAJB9.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Light microscopy</strong> – The light microscopic findings are nondiagnostic and variable, showing patterns that may be seen with other glomerulonephritides [<a href="#rid3">3,4</a>]. These include focal mesangial (the most common) or diffuse proliferative or membranoproliferative glomerulonephritis (with or without crescent formation), a membranous pattern, and mesangial expansion with amorphous material that may be suggestive of amyloidosis or light chain deposition disease (<a class="graphic graphic_picture graphicRef74384" href="/z/d/graphic/74384.html" rel="external">picture 1</a>). In a study of 66 patients, the most common histologic patterns were mesangioproliferative/sclerosing glomerulonephritis and membranoproliferative glomerulonephritis, which were observed in 71 percent and 15 percent, respectively [<a href="#rid4">4</a>]. A crescentic glomerulonephritis can be seen in 17 to 50 percent of cases [<a href="#rid2">2-4,15,16</a>], but cases with &gt;50 percent of glomeruli involvement are rare.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Immunofluorescence</strong> – Immunofluorescence microscopy is positive for immunoglobulin G (IgG), C3, and both kappa and lambda (ie, polyclonal) light chains [<a href="#rid1">1,4,11,17</a>]. There is usually predominant deposition of some IgG subclasses, particularly IgG4 and to a lesser extent IgG1. In a single-center series of 61 patients with fibrillary glomerulonephritis, immunofluorescence microscopy in 19 cases found polytypic deposits (all with IgG1 and IgG4 subclasses) in 15, with the remaining four having monotypic deposits (two IgG1 and two IgG4) [<a href="#rid3">3</a>]. Immunoglobulin A (IgA), immunoglobulin M (IgM), and C1q deposition may also be seen [<a href="#rid4">4</a>]. The fibrillary deposits may be so extensive that the IgG deposition may be linear, similar to that seen in anti-glomerular basement membrane antibody disease (<a class="graphic graphic_picture graphicRef61547" href="/z/d/graphic/61547.html" rel="external">picture 2</a>) [<a href="#rid1">1,6,16,18</a>]. Extraglomerular staining, most commonly involving the tubular basement membranes, has been reported in 30 to 50 percent of cases [<a href="#rid15">15,19</a>]. Rare cases of immunoglobulin-negative fibrillary glomerulonephritis have also been described [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent2">The detection of monotypic deposits by standard frozen section immunofluorescence should be confirmed by paraffin immunofluorescence, which may reveal "masked" polytypic deposits in nearly one-half of cases and thereby prevent the misdiagnosis of these patients with monoclonal fibrillary glomerulonephritis [<a href="#rid21">21</a>]. Immunofluorescence staining for immunoglobulin heavy chain/light chain on kidney biopsies can also be used to confirm or exclude monoclonality in these cases [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Electron microscopy</strong> – Electron microscopy shows random fibrillar deposits in the mesangium and glomerular capillary walls that are clearly distinct from those seen in amyloidosis (<a class="graphic graphic_picture graphicRef82244" href="/z/d/graphic/82244.html" rel="external">picture 3</a>). The fibrils are larger than those in amyloidosis (16 to 24 nm in fibrillary glomerulonephritis versus 10 nm in diameter in amyloidosis). The fibrils in fibrillary glomerulonephritis (<a class="graphic graphic_picture graphicRef72813" href="/z/d/graphic/72813.html" rel="external">picture 4</a>) are randomly arranged, whereas microtubules observed in immunotactoid glomerulopathy form parallel bundles [<a href="#rid3">3,10</a>]. (See <a class="local">'Immunotactoid glomerulopathy'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Congo red staining</strong> – In contrast to amyloid fibrils, the fibrils in fibrillary glomerulonephritis usually do not stain with Congo red or thioflavine-T or with antibodies to a specific light chain (either lambda or kappa) or to serum amyloid A [<a href="#rid1">1,2,4</a>]. However, one study described a series of patients with fibrillary glomerulonephritis whose glomerular deposits were Congo red positive [<a href="#rid23">23</a>]. Given these findings, the presence or absence of Congo red staining should not solely be used to distinguish between fibrillary glomerulonephritis and renal amyloidosis. Other diagnostic methods, such as mass spectrometry and immunohistochemistry (for DNAJB9), are important in making this distinction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – Fibrillary glomerulonephritis was initially considered to be an idiopathic disorder [<a href="#rid3">3</a>]. However, approximately 30 to 50 percent of patients have a history of malignancy (4 to 23 percent), monoclonal gammopathy (4 to 16 percent), or autoimmune disease (13 to 30 percent of patients) [<a href="#rid4">4,7</a>]. A link between fibrillary glomerulonephritis and hepatitis C has also been described [<a href="#rid4">4,19,23,24</a>]. Other common comorbidities include diabetes mellitus and hypertension, reported in approximately 30 and 75 percent of cases, respectively. (See <a class="local">'Associated diseases'</a> below.)</p><p></p><p class="bulletIndent1">Proteomic studies have identified DnaJ heat shock protein family (Hsp40) member B9 (DNAJB9) as a potential novel, highly specific biomarker for the diagnosis of fibrillary glomerulonephritis [<a href="#rid13">13,14</a>]. DNAJB9, a protein involved in the endoplasmic reticulum stress response, was found to be highly enriched in the glomeruli of patients with fibrillary glomerulonephritis but not in those of patients with amyloidosis or other glomerular diseases or healthy subjects (<a class="graphic graphic_picture graphicRef122159" href="/z/d/graphic/122159.html" rel="external">picture 5</a>). Immunofluorescence microscopy confirmed positive staining for DNAJB9 in glomerular capillary walls and the mesangium of all patients with fibrillary glomerulonephritis, while no staining was observed in patients with amyloidosis or other glomerular diseases or healthy controls [<a href="#rid13">13-15</a>]. In addition, immunoelectron microscopy demonstrated localization of DNAJB9 to fibrils in fibrillary glomerulonephritis but not to amyloid fibrils or immunotactoid glomerulopathy microtubules [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1">The role of DNAJB9 in the pathogenesis of fibrillary glomerulonephritis is unclear. Colocalization of staining for DNAJB9 and IgG within glomerular deposits suggests that DNAJB9 could represent a putative autoantigen in fibrillary glomerulonephritis. However, a circulating DNAJB9 autoantibody has not been identified in these patients to support this theory [<a href="#rid13">13,15</a>]. Another possibility is that DNAJB9 may be a protein that secondarily binds to misfolded IgG molecules by recognizing aggregation-prone motifs [<a href="#rid7">7,25</a>]. This hypothesis could explain the poor response to <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> and other immunosuppressive agents in patients with fibrillary glomerulonephritis. Further studies are required to determine the role of DNAJB9 in the pathogenesis of this disease. (See <a class="local">'Treatment'</a> below.)</p><p></p><p class="bulletIndent1">Mass spectometry studies have shown that significant complement activation is present in fibrillary glomerulonephritis from C3- and C4A-based pathways. Terminal pathway complement proteins and regulatory proteins of the complement pathway are also present within glomerular deposits [<a href="#rid26">26</a>]. </p><p></p><p class="bulletIndent1">Case reports of a familial form of fibrillary glomerulonephritis have been described [<a href="#rid27">27-30</a>]. These cases predated the discovery of DNAJB9 as a disease marker, and DNAJB9 staining to confirm the diagnosis was not performed.</p><p></p><p class="headingAnchor" id="H2491515432"><span class="h3">Immunotactoid glomerulopathy</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathology</strong> – Immunotactoid glomerulopathy, in contrast to fibrillary glomerulonephritis, is characterized by the formation of microtubules on electron microscopy. In addition, these microtubules are typically much larger than the fibrils in fibrillary glomerulonephritis (17 to 52 versus 16 to 24 nm in diameter) (<a class="graphic graphic_picture graphicRef72813" href="/z/d/graphic/72813.html" rel="external">picture 4</a>) [<a href="#rid2">2,6,9,10,31</a>]. However, due to the overlap, substructure diameter alone is insufficient to distinguish between fibrillary glomerulonephritis and immunotactoid glomerulopathy. Immunostaining for the marker DNAJB9, which is positive among patients with fibrillary glomerulonephritis (see <a class="local">'Fibrillary glomerulonephritis'</a> above), is uniformly negative.</p><p></p><p class="bulletIndent1">Most patients have either a circulating paraprotein or monoclonal immunoglobulin deposition in the glomeruli on immunofluorescence microscopy with a restricted light chain, either kappa or lambda [<a href="#rid3">3,6,9,11,31,32</a>] (see <a class="local">'Diagnosis'</a> below). Deposits are almost always composed of IgG (predominantly IgG1 or IgG2) [<a href="#rid31">31,33</a>]. A case of light chain–only immunotactoid glomerulopathy has been described [<a href="#rid34">34</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – Most cases of immunotactoid glomerulopathy are associated with a lymphocytic or plasma cell disorder, either indolent according to hematologic criteria (and corresponding to monoclonal gammopathy of renal significance) or symptomatic. Some authors call this disorder glomerulonephritis with organized monoclonal microtubular immunoglobulin deposits (GOMMID) [<a href="#rid11">11</a>]. Tubulointerstitial infiltration with malignant B cells may be observed in patients with immunotactoid glomerulopathy associated with symptomatic chronic lymphocytic leukemia or B cell lymphoma. The absence of detectable circulating cryoglobulins is required to establish the diagnosis of immunotactoid glomerulopathy.</p><p></p><p class="bulletIndent1">In a study of 14 patients with immunotactoid glomerulopathy, glomerular deposits were composed of monotypic IgG in 13 patients who also had a <strong>monoclonal</strong> immunoglobulin of the same isotype in the serum and/or the cytoplasm of lymphocytes [<a href="#rid11">11</a>]. In addition, a lymphoproliferative disease was observed in seven patients. By comparison, none of nine patients with fibrillary glomerulonephritis had a paraprotein or a lymphoproliferative disorder, while eight of the nine patients had <strong>polyclonal</strong> immunoglobulin glomerular deposits.</p><p></p><p class="bulletIndent1">Similar findings were reported in another series of 16 patients with immunotactoid glomerulopathy, in whom a serum monoclonal protein was detected in 63 percent and hypocomplementemia was present in 46 percent [<a href="#rid35">35</a>]. A hematologic malignancy was identified in six (38 percent) patients, including three with chronic lymphocytic leukemia, two with lymphoplasmacytic lymphoma, and two with multiple myeloma.</p><p></p><p class="bulletIndent1">Thus, a careful search for a B cell or plasma cell lymphoproliferative disease should be part of the routine evaluation of patients with immunotactoid glomerulopathy. (See <a class="local">'Diagnosis'</a> below.)</p><p></p><p class="headingAnchor" id="H7"><span class="h2">Clinical features</span></p><p class="headingAnchor" id="H676232816"><span class="h3">Typical presentation</span><span class="headingEndMark"> — </span>The presenting clinical features of fibrillary glomerulonephritis and immunotactoid glomerulopathy are similar to those in other forms of glomerular disease [<a href="#rid2">2,4,5,8,10,31,35,36</a>]. (See  <a class="medical medical_review" href="/z/d/html/3041.html" rel="external">"Glomerular disease: Evaluation and differential diagnosis in adults"</a>.)</p><p>The largest reported experience described the clinical features in 186 patients with fibrillary glomerulonephritis or immunotactoid glomerulopathy [<a href="#rid5">5</a>]. Approximately 90 percent of patients had fibrillary glomerulonephritis, but the clinical findings were similar in both disorders. Both affect middle-aged individuals, with the reported age at diagnosis ranging from 41 to 80 years [<a href="#rid7">7,35</a>].</p><p>The following findings were noted at presentation:</p><p class="bulletIndent1"><span class="glyph">●</span>Hematuria in 70 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Proteinuria in 100 percent, with nephrotic syndrome (protein excretion ≥3.5 g/day) in 70 to 75 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Kidney function impairment (serum creatinine ≥1.5 mg/dL [133 micromol/L]) in 50 to 55 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension in 65 to 70 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Monoclonal gammopathy in 16 to 63 percent</p><p></p><p>A similar spectrum of findings was reported in two independent series of immunotactoid glomerulopathy [<a href="#rid31">31,33</a>]. In both of these studies, 33 percent of patients had hypocomplementemia. In one study, a serum or urine monoclonal protein was detected more frequently among patients with monoclonal immunotactoid glomerulopathy compared with those with polyclonal immunotactoid glomerulopathy (50 and 42 percent versus 16 and 0 percent, respectively) [<a href="#rid31">31</a>].</p><p class="headingAnchor" id="H194907505"><span class="h3">Associated diseases</span><span class="headingEndMark"> — </span>Most cases of fibrillary glomerulonephritis were previously considered idiopathic. However, 30 to 50 percent of cases of fibrillary glomerulonephritis are associated with malignancy, monoclonal gammopathy, autoimmune disease, or infections [<a href="#rid3">3-5,11,37</a>].</p><p>The frequency with which these associated disorders occur was illustrated in a report of 66 patients with fibrillary glomerulonephritis [<a href="#rid4">4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Fifteen patients (23 percent) had an associated malignancy, which was diagnosed 15 years before to 10 years after the onset of kidney disease [<a href="#rid4">4</a>]. Six of the 15 malignancies were due to multiple myeloma or leukemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Eleven patients (17 percent) had a monoclonal gammopathy, which is similar to the 15 percent incidence reported in another study [<a href="#rid3">3</a>]. However, subsequent studies have found that the vast majority of cases of DNAJB9-positive fibrillary glomerulonephritis are not associated with monoclonal gammopathy, whereas rare cases of DNAJB9-negative fibrillary glomerulonephritis (&lt;2 percent) appear to be associated with a monoclonal gammopathy of renal significance [<a href="#rid21">21</a>]. Whether these rare DNAJB9-negative cases are truly fibrillary glomerulonephritis is questionable. (See  <a class="medical medical_review" href="/z/d/html/109635.html" rel="external">"Diagnosis and treatment of monoclonal gammopathy of renal significance"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ten patients (15 percent) had autoimmune disorders (most often Crohn disease, lupus, Graves' disease, and immune thrombocytopenia [ITP]).</p><p></p><p>Cases of fibrillary glomerulonephritis associated with Sjögren's disease [<a href="#rid38">38,39</a>], rheumatoid arthritis [<a href="#rid40">40</a>], Behçet syndrome [<a href="#rid41">41</a>], immune checkpoint inhibitor therapy [<a href="#rid42">42</a>], and COVID-19 vaccination [<a href="#rid43">43</a>] have also been described</p><p>By contrast, immunotactoid glomerulopathy is more frequently associated with chronic lymphocytic leukemia and related B cell lymphomas or multiple myeloma [<a href="#rid3">3,5,11,31,35,37</a>]. In the largest series of 73 patients, 48 (66 percent) had a hematologic disorder, including lymphoma in 41 percent (mainly chronic lymphocytic leukemia/small lymphocytic lymphoma), monoclonal gammopathy in 20 percent, and multiple myeloma in 6 percent [<a href="#rid31">31</a>]. Patients with immunotactoid glomerulopathy and monoclonal deposits in the kidney had a much higher incidence of hematologic disorders than those with polyclonal deposits.</p><p>Both fibrillary glomerulonephritis and immunotactoid glomerulopathy have been described in patients with hepatitis C virus (HCV) infection [<a href="#rid4">4,24</a>]. Fibrillary glomerulonephritis has been also described in association with anti-glomerular basement membrane disease [<a href="#rid44">44</a>].</p><p class="headingAnchor" id="H1886827580"><span class="h3">Rare extrarenal involvement</span><span class="headingEndMark"> — </span>The fibril or microtubule deposition in these conditions is almost always limited to the kidney [<a href="#rid8">8</a>]. There are, however, a small number of observations suggesting a <strong>systemic</strong> component in rare patients with fibrillary glomerulonephritis and immunotactoid glomerulopathy:</p><p class="bulletIndent1"><span class="glyph">●</span>Both disorders can recur in the kidney transplant [<a href="#rid4">4,5,9,45,46</a>]. However, in one series of patients with fibrillary deposits (fibrillary glomerulonephritis or monoclonal gammopathy with fibrillary deposits), only those with a monoclonal gammopathy developed recurrent disease [<a href="#rid46">46</a>]. Thus, it is important to distinguish patients with monoclonal gammopathy with fibrillary deposits from those with true fibrillary glomerulonephritis. (See <a class="local">'End-stage kidney disease'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Two cases of patients with fibrillary glomerulonephritis and extrarenal involvement have been described. One case report described a patient with fibrillary glomerulonephritis who had fibril deposition in the alveolar capillaries, leading to fatal pulmonary hemorrhage [<a href="#rid47">47</a>]. However, it should be recognized that distinguishing alveolar matrix fibrils from true fibrillary fibers can be difficult [<a href="#rid48">48</a>]. A second case report detailed the autopsy of a patient with fibrillary glomerulonephritis who was found to have fibrils in the kidney and spleen but no other organs [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similarly, a few cases of immunotactoid glomerulopathy with extrarenal involvement have been reported: two with immunotactoid deposition in the bone marrow [<a href="#rid50">50,51</a>], two with skin involvement manifesting as leukocytoclastic skin vasculitis [<a href="#rid11">11,52</a>], and one with peripheral neuropathy due to perineural monotypic IgG deposits with similar ultrastructural microtubular organization to the glomerular deposits [<a href="#rid11">11</a>].</p><p></p><p class="headingAnchor" id="H1820454971"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of fibrillary glomerulonephritis or immunotactoid glomerulopathy is made by kidney biopsy in a patient with suspected glomerular disease. Fibrillary glomerulonephritis can be distinguished from immunotactoid glomerulopathy on the basis of electron microscopy as well as positive immunofluorescence staining for DNAJB9. (See <a class="local">'Pathology and pathogenesis'</a> above and  <a class="medical medical_review" href="/z/d/html/3041.html" rel="external">"Glomerular disease: Evaluation and differential diagnosis in adults"</a>.)</p><p>There are no established, noninvasive laboratory tests to diagnose fibrillary glomerulonephritis or immunotactoid glomerulopathy. However, one study found that serum levels of DNAJB9 were fourfold higher in patients with fibrillary glomerulonephritis compared with healthy controls and patients with multiple myeloma, immunoglobulin light chain (AL) amyloidosis, and other glomerular diseases (including immunotactoid glomerulopathy) [<a href="#rid53">53</a>]. Serum DNAJB9 levels predicted a diagnosis of fibrillary glomerulonephritis with a sensitivity and specificity of 67 and 98 percent, respectively. These findings suggest that DNAJB9 could be useful as a serum biomarker for the diagnosis of fibrillary glomerulonephritis, although validation in larger, prospective studies is needed. Testing for serum DNAJB9 is not yet commercially available.</p><p>Patients with fibrillary glomerulonephritis or immunotactoid glomerulopathy should be evaluated for secondary causes as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with a diagnosis of fibrillary glomerulonephritis should be screened for malignancy, monoclonal gammopathy, autoimmune disease, and HCV infection (see <a class="local">'Associated diseases'</a> above). The temporal relationship with these diseases is variable. As an example, malignancy may precede, be concomitant with, or follow the diagnosis by many years [<a href="#rid54">54</a>]. Thus, ongoing monitoring is warranted in these patients. We perform the following tests at the time the kidney disease is diagnosed:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Complete blood count with differential (should be repeated at least annually)</p><p class="bulletIndent2"><span class="glyph">•</span>Serum and urine protein electrophoresis with immunofixation and serum free light chains (should be repeated at least annually)</p><p class="bulletIndent2"><span class="glyph">•</span>Tests for HCV and HIV</p><p class="bulletIndent2"><span class="glyph">•</span>Antinuclear antibody (ANA) and, if positive, anti-double stranded DNA (anti-dsDNA), anti-Sm, anti-Ro/SSA, and anti-LA/SSB</p><p class="bulletIndent2"><span class="glyph">•</span>C3 and C4 complement levels</p><p class="bulletIndent2"><span class="glyph">•</span>Cryoglobulins</p><p class="bulletIndent2"><span class="glyph">•</span>Chest radiograph</p><p></p><p class="bulletIndent1">Patients without known cancer who are diagnosed with fibrillary glomerulonephritis should undergo age- and risk-appropriate cancer screening, if not already performed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with a diagnosis of immunotactoid glomerulopathy should be screened for monoclonal gammopathy with serum and urine electrophoresis with immunofixation and serum free light chain levels. In those with confirmed monotypic deposits and/or monoclonal gammopathy, additional investigations may be required to characterize the nature of the underlying clonal disorder, including bone marrow examination with flow cytometry, and, when a B cell lymphoproliferative disease is suspected, flow cytometry of blood lymphocytes; computed tomography (CT) scan of the chest, abdomen, and pelvis; and/or positron emission tomography (PET) scan. (See  <a class="medical medical_review" href="/z/d/html/109635.html" rel="external">"Diagnosis and treatment of monoclonal gammopathy of renal significance", section on 'Subsequent evaluation of patients with confirmed MGRS'</a>.)</p><p></p><p class="headingAnchor" id="H9"><span class="h2">Treatment</span></p><p class="headingAnchor" id="H2588178553"><span class="h3">Our approach to therapy</span><span class="headingEndMark"> — </span>Fibrillary and immunotactoid glomerular disease are difficult to treat and there are no randomized controlled trials to guide optimal therapy. Although we consider these disorders to be two pathologically distinct processes, our approach to treatment in patients <strong>without a secondary cause</strong> is similar for both and is based primarily upon the limited available data from retrospective studies and case series and our own clinical experience. There are <strong>no </strong>therapies that have been clearly shown to be beneficial for either fibrillary glomerulonephritis or immunotactoid glomerulopathy. Patients who have a possible secondary cause for these disorders, such as malignancy, monoclonal gammopathy, infection, or autoimmune disease, may benefit from treatment of the underlying disorder. This is especially true for patients with a monoclonal gammopathy who may benefit from B cell or plasma cell targeted therapy. In patients with idiopathic disease, our approach to treatment is generally determined by the severity of kidney dysfunction. (See <a class="local">'Patients with secondary causes'</a> below.)</p><p>A case series of 27 patients synthesized the data from these and 197 patients reported in five previous case series; during an average of four to five years of follow-up, four patients (2 percent) had complete remission, 12 (5 percent) had partial remission, 32 (14 percent) had progressive kidney disease, and 96 (45 percent) developed end-stage kidney disease (ESKD) [<a href="#rid19">19</a>]. Nearly all were treated with angiotensin inhibition, and 85 patients received immunosuppressive therapy. Those with milder disease were more likely to attain a complete or partial remission. In two of these six series, for example, 7 of 15 patients had mild disease at the time of kidney biopsy as defined by a normal estimated glomerular filtration rate (eGFR) and non-nephrotic-range proteinuria [<a href="#rid4">4,19</a>].</p><p class="headingAnchor" id="H1361400767"><span class="h4">Patients with secondary causes</span><span class="headingEndMark"> — </span>As described above, malignancy, monoclonal gammopathy, and autoimmune diseases occur in more than one-third of patients with fibrillary glomerulonephritis, and chronic lymphocytic leukemia and related B cell lymphomas have been associated with immunotactoid glomerulopathy. Both fibrillary glomerulonephritis and immunotactoid glomerulopathy have been associated with HCV infection. Thus, a careful search for a secondary cause should be part of the routine evaluation of these disorders. Ongoing screening may be warranted since these disorders can first be detected <strong>after</strong> the diagnosis of the kidney disease. (See <a class="local">'Associated diseases'</a> above and <a class="local">'Diagnosis'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span>In patients with fibrillary glomerulonephritis who have an associated malignancy or autoimmune disorder, we advocate for treatment of these conditions as appropriate in consultation with a hematologist/oncologist or rheumatologist, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with fibrillary glomerulonephritis or immunotactoid glomerulopathy who have an associated monoclonal gammopathy (ie, patient has monotypic deposits on immunofluorescence staining of the kidney biopsy or a detectable serum or urine monoclonal protein) with or without a detectable plasma or B cell clone, we treat with therapy directed against the pathologic clone responsible for the monoclonal gammopathy [<a href="#rid55">55,56</a>]. This approach is similar to that used for patients with proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) [<a href="#rid57">57</a>], as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/109635.html" rel="external">"Diagnosis and treatment of monoclonal gammopathy of renal significance", section on 'Patients with PGNMID'</a>.)</p><p></p><p class="bulletIndent1">In patients with immunotactoid glomerulopathy who have an associated monoclonal gammopathy but no detectable plasma or B cell clone, treatment with rituximab-based therapy to eradicate a "hypothesized B cell clone" is a potential initial option, given the high incidence of underlying B cell disorders in immunotactoid glomerulopathy [<a href="#rid33">33,56</a>]. There is one case report of successful treatment with bortezomib-based therapy [<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with fibrillary glomerulonephritis or immunotactoid glomerulopathy who have chronic HCV infection and have not yet received therapy, we advocate for treatment of HCV as appropriate. However, evidence that treating HCV infection results in improvement of fibrillary glomerulonephritis is lacking. (See  <a class="medical medical_review" href="/z/d/html/3673.html" rel="external">"Overview of the management of chronic hepatitis C virus infection"</a>.)</p><p></p><p>In addition to addressing the underlying disorder, we administer therapies aimed at reducing proteinuria, controlling blood pressure, and slowing the progression of kidney disease, as discussed below. (See <a class="local">'Estimated GFR ≥60 mL/min/1.73 m2 and proteinuria &lt;3.5 g/day'</a> below.)</p><p>Patients should be routinely monitored during treatment for signs of kidney disease progression. We typically monitor serum creatinine concentration and urine protein excretion every three to six months. If patients do not show signs of improvement of their kidney disease following treatment of the underlying disorder, treatment with immunosuppressive therapy can be considered on a case-by-case basis. (See <a class="local">'Estimated GFR &lt;60 mL/min/1.73 m2 or proteinuria &gt;3.5 g/day'</a> below.)</p><p>Effective therapy directed at the underlying disorder appears to have a beneficial effect on the kidney disease [<a href="#rid11">11,35,37,59,60</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 12 patients with fibrillary glomerulonephritis or immunotactoid glomerulopathy who had nephrotic syndrome and a lymphoproliferative disease and/or monoclonal gammopathy, complete or partial remission of the nephrotic syndrome occurred in 10 of the 12 patients after the initiation of chemotherapy, with a parallel improvement in the hematologic disease [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a series of 27 patients with immunotactoid glomerulopathy, 18 had a bone marrow or peripheral blood clonal disorder (16 lymphocytic and two plasmacytic) [<a href="#rid33">33</a>]. Among the 21 patients who received treatment with alkylating agents or rituximab- or bortezomib-based chemotherapy, 18 achieved a kidney response. After a median of 40 months, 16 patients had a sustained kidney response, seven developed ESKD, and six died. A hematologic response after clone-directed chemotherapy was associated with favorable outcomes. Similar findings were reported in another retrospective study, in which patients with monoclonal immunotactoid glomerulopathy who were treated with clone-directed therapy had higher rates of remission (50 versus 24 percent) and lower rates of ESKD (11 versus 53 percent) compared with those with polyclonal immunotactoid glomerulopathy who received immunosuppressive therapy or supportive care only [<a href="#rid31">31</a>].</p><p></p><p class="headingAnchor" id="H3928280125"><span class="h4">Patients with idiopathic disease</span><span class="headingEndMark"> — </span>In patients with fibrillary glomerulonephritis or immunotactoid glomerulopathy who do not have a secondary cause of their kidney disease, our approach to treatment depends upon the severity of their kidney disease.</p><p class="headingAnchor" id="H2805340580"><span class="h5">Estimated GFR ≥60 mL/min/1.73 m2 and proteinuria &lt;3.5 g/day</span><span class="headingEndMark"> — </span>In patients with relatively preserved kidney function (estimated glomerular filtration rate [eGFR] of ≥60 mL/min/1.73 m<sup>2</sup>) <strong>and </strong>subnephrotic-range proteinuria (&lt;3.5 g/day), we prefer a more conservative initial approach to treatment. We treat these patients with antiproteinuric therapy (angiotensin-converting enzyme [ACE] inhibitors or angiotensin receptor blockers [ARBs]), blood pressure control, and dietary sodium restriction indefinitely. In addition, we administer lipid-lowering therapy as appropriate for patients with hyperlipidemia and advocate weight reduction in patients who are overweight or obese. These general issues are discussed in detail elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults", section on 'Effect of renin-angiotensin system inhibitors on progression of CKD'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7178.html" rel="external">"Dietary recommendations for patients with nondialysis chronic kidney disease", section on 'Salt intake'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7204.html" rel="external">"Lipid management in patients with nondialysis chronic kidney disease"</a>.)</p><p></p><p>We monitor the patient by obtaining serum creatinine concentration and urine protein excretion every three to six months. In patients who respond to conservative therapy (ie, proteinuria decreases and serum creatinine and eGFR remain stable), we continue these measures and monitor the patient closely for signs of disease progression. Patients who develop progressive loss of kidney function or worsening proteinuria despite maximal conservative therapy should be considered for immunosuppressive therapy, as discussed below. (See <a class="local">'Estimated GFR &lt;60 mL/min/1.73 m2 or proteinuria &gt;3.5 g/day'</a> below.)</p><p>The benefits of conservative antiproteinuric therapy in patients with fibrillary glomerulonephritis or immunotactoid glomerulopathy are unclear. In a study of 61 patients with fibrillary glomerulonephritis who were followed for a mean of 52 months, 16 patients were treated with angiotensin blockade alone [<a href="#rid4">4</a>]. Two of these patients had complete remission, two had partial remission, eight had progressive kidney disease, and four progressed to ESKD. By contrast, in another study of 27 patients with fibrillary glomerulonephritis followed for a mean of 46 months, none of the 14 patients treated with angiotensin blockade alone attained a complete or partial remission [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H1153801060"><span class="h5">Estimated GFR &lt;60 mL/min/1.73 m2 or proteinuria &gt;3.5 g/day</span><span class="headingEndMark"> — </span>There are no randomized trials to guide the optimal therapy in patients with fibrillary glomerulonephritis or immunotactoid glomerulopathy who have abnormal kidney function (estimated glomerular filtration rate [eGFR] &lt;60 mL/min/1.73 m<sup>2</sup>) or nephrotic range proteinuria (&gt;3.5 g/day), and no immunosuppressive therapies have been clearly shown to be beneficial. However, given the generally poor prognosis associated with these disorders (see <a class="local">'Prognosis'</a> below), it is reasonable to offer a trial of immunosuppressive therapy after discussing the potential risks and benefits of treatment with the patient. We prefer the use of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, administered either as four weekly doses of 375 mg/m<sup>2</sup> intravenously (IV) or as 1 g IV initially followed 14 days later by another 1 g dose, based upon observational data suggesting a benefit in some patients. In addition, we administer conservative measures used to control blood pressure and reduce protein excretion for the duration of the disease, as described above. (See <a class="local">'Estimated GFR ≥60 mL/min/1.73 m2 and proteinuria &lt;3.5 g/day'</a> above.)</p><p>We monitor the patient by obtaining serum creatinine concentration and urine protein excretion every three to six months. In patients who respond to <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> therapy (ie, proteinuria decreases and/or serum creatinine and eGFR remain stable), we continue monitoring the patient for signs of disease progression every three to six months. If proteinuria decreases but the patient does not go into complete remission (ie, proteinuria &lt;300 mg/24 hours) after a minimum of six months follow-up, we measure the patient’s B cell counts (CD19-positive cells by flow cytometric analysis). If the CD19-positive B cell count is &gt;5 per microL, we redose the patient with a single dose of rituximab 1 g IV. If, after the second course of rituximab, proteinuria stabilizes but the patient does not achieve complete remission, we assume that residual proteinuria is due to chronic damage and continue conservative therapy without redosing rituximab. In patients who do not respond to rituximab therapy, we typically do not offer additional immunosuppressive therapy, since the risks of treatment (eg, infection, malignancy) likely outweigh any potential benefits.</p><p>Some but not all reports suggest that <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> may be associated with complete or partial remission of proteinuria in patients with fibrillary glomerulonephritis [<a href="#rid4">4,19,30,59,61,62</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>One case series reported outcomes of 12 patients with fibrillary glomerulonephritis who were treated with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> (1 g IV for two doses or 375 mg/m<sup>2</sup> for four weekly doses); all patients received an ACE inhibitor or ARB [<a href="#rid62">62</a>]. At baseline, median serum creatinine was 2.1 mg/dL (range 0.7 to 2.7 mg/dL), median eGFR was 39 mL/min/1.73 m<sup>2</sup> (range 21 to 98 mL/min/1.73 m<sup>2</sup>), and median proteinuria was 4.5 g/day (range 0.2 to 7.5 g/day). Four patients did not develop progressive kidney disease, three had progressive kidney disease without reaching ESKD, and five patients progressed to ESKD. Patients who did not develop progressive disease had lower baseline serum creatinine values, higher eGFR, and a shorter median duration from diagnosis to treatment compared with those who progressed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 27 adults with fibrillary glomerulonephritis, all patients were given renin-angiotensin system inhibitors and 13 received immunosuppressive therapy, including <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> (seven patients) and <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> (three patients). After a median 46-month follow-up, kidney response occurred in 6 of 13 patients who received immunosuppressive therapy with rituximab (five patients) or cyclophosphamide (one patient). By contrast, chronic kidney disease progressed in 12 of 14 patients who were not given immunosuppressive therapy, 10 of whom reached ESKD [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A third series examined outcomes of 11 patients with idiopathic fibrillary glomerulonephritis who received <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> (1 g intravenously [IV] on days 1 and 15, followed by an identical regimen six months later) [<a href="#rid63">63</a>]. At 12 months, there was no significant difference in median 24-hour creatinine clearance compared with baseline (47.7 versus 43.7 mL/min/body surface area, respectively). Proteinuria decreased from a median of 4428 mg/day to 1936 mg/day, although this change was not statistically significant. One patient achieved complete remission of proteinuria, and two patients had partial remission of proteinuria.</p><p></p><p><a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> also appeared to be effective in a case report of recurrent immunotactoid glomerulopathy in the transplant that had not responded to conventional immunosuppressive therapy [<a href="#rid64">64</a>]. (See <a class="local">'End-stage kidney disease'</a> below.)</p><p>Immunosuppressive therapy with glucocorticoids with or without other agents (eg, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">melphalan</a>, <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>, and rapamycin) has been reported in uncontrolled studies with limited and inconsistent results [<a href="#rid3">3,4,10,19,65</a>].</p><p>It has been suggested that patients with idiopathic fibrillary glomerulonephritis or immunotactoid glomerulopathy should be treated according to the findings on light microscopy [<a href="#rid3">3</a>]. The rationale for such an approach is based upon the observation that patients with a membranoproliferative pattern of injury progress faster to ESKD than patients with a mesangioproliferative pattern [<a href="#rid4">4</a>]. However, as discussed above, the mesangioproliferative pattern may represent an earlier stage of pathogenic process rather than milder disease. Consistent with this hypothesis is the observation that, when kidney histology was stratified by immunosuppressive therapy, there was no effect of immunosuppression on the rate of progression to ESKD. (See <a class="local">'Prognosis'</a> below.)</p><p class="headingAnchor" id="H851606435"><span class="h5">Patients with crescentic glomerulonephritis</span><span class="headingEndMark"> — </span>In patients presenting with a rapidly progressive glomerulonephritis and crescents on kidney biopsy, we suggest treatment with high-dose glucocorticoids and <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> as used in other forms of crescentic glomerulonephritis [<a href="#rid66">66,67</a>]. However, a series of 21 patients presenting with crescentic fibrillary glomerulonephritis showed a poor kidney prognosis regardless of immunosuppressive therapy used, with only one patient showing kidney survival at 12 months [<a href="#rid68">68</a>]. (See  <a class="medical medical_review" href="/z/d/html/3113.html" rel="external">"Overview of the classification and treatment of rapidly progressive (crescentic) glomerulonephritis", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H10"><span class="h3">End-stage kidney disease</span><span class="headingEndMark"> — </span>Dialysis or kidney transplantation can be performed in patients with fibrillary glomerulonephritis or immunotactoid glomerulopathy who progress to ESKD. With kidney transplantation, recurrent disease can develop in the allograft in both disorders [<a href="#rid4">4,5,45,46,69</a>], but the rate of progression is usually slower than in the native kidney [<a href="#rid5">5,45,46,69,70</a>]. The rate of recurrence appears be higher in patients who have a monoclonal gammopathy [<a href="#rid46">46</a>], which occurs in both disorders. (See <a class="local">'Associated diseases'</a> above.)</p><p>Specific data on the rate of recurrence in fibrillary glomerulonephritis are limited to relatively small numbers of patients [<a href="#rid4">4,45,46,64,71-73</a>]. The following findings are illustrative:</p><p class="bulletIndent1"><span class="glyph">●</span>One report evaluated 14 patients with DNAJB9-positive fibrillary glomerulonephritis who underwent kidney transplantation and had protocol allograft biopsies at 4, 12, 24, 60, and 120 months posttransplantation [<a href="#rid71">71</a>]. At a median of 5.7 years posttransplantation, three patients developed biopsy-proven recurrent disease; the median time to recurrence was 10.2 years. The remaining 11 patients had no evidence of histologic recurrence on the last posttransplant biopsy, although median follow-up time in these patients was less at 4.4 years. In three patients (21 percent), a monoclonal protein was detectable in serum obtained pretransplantation; none of these patients developed recurrent fibrillary glomerulonephritis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A study from the Australia and New Zealand Dialysis and Transplant Registry reported the prognosis of 55 patients with ESKD due to fibrillary glomerulonephritis and 11 patients with immunotactoid glomerulopathy [<a href="#rid72">72</a>]. Patients with fibrillary glomerulonephritis had survival rates on dialysis that were comparable with those of patients with other causes of ESKD. However, patients with immunotactoid glomerulopathy had inferior survival on dialysis. Among patients who were transplanted, recurrent disease occurred in 1 of 13 patients with fibrillary glomerulonephritis and 1 of 4 patients with immunotactoid glomerulopathy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a report of two patients with immunotactoid glomerulopathy who underwent kidney transplantation plus two others in case reports, two developed recurrent disease at two- to six-year follow-up [<a href="#rid45">45</a>]. In other case reports of immunotactoid glomerulopathy, more aggressive immunosuppressive therapy (including plasma exchange, pulse <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a>, and <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> pulses rather than <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>) [<a href="#rid64">64</a>] or the use of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> [<a href="#rid73">73</a>] appeared to be beneficial.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A case of familial fibrillary glomerulonephritis recurring following a living-related kidney transplant has been reported [<a href="#rid74">74</a>].</p><p></p><p>In summary, kidney transplantation is a reasonable therapeutic option for patients with fibrillary glomerulonephritis who develop ESKD. In those with an associated monoclonal gammopathy, a thorough evaluation of the monoclonal gammopathy should be addressed prior to transplantation. Immunotactoid glomerulopathy may recur in the kidney allograft and may result in loss of the allograft [<a href="#rid31">31,33</a>]. In patients with monoclonal immunotactoid glomerulopathy, treatment of the monoclonal gammopathy should be addressed prior to transplantation.</p><p class="headingAnchor" id="H486368746"><span class="h2">Prognosis</span><span class="headingEndMark"> — </span>Approximately 40 to 50 percent of reported patients with fibrillary glomerulonephritis or immunotactoid glomerulopathy develop ESKD within two to six years [<a href="#rid1">1-4,6,8,10,19,30</a>]. In a single-center series that included 61 patients with fibrillary glomerulonephritis, the mean time to ESKD varied according to the histologic findings on light microscopy [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>7 months with diffuse sclerosing glomerulonephritis</p><p class="bulletIndent1"><span class="glyph">●</span>20 months with diffuse proliferative glomerulonephritis</p><p class="bulletIndent1"><span class="glyph">●</span>44 months with membranoproliferative glomerulonephritis</p><p class="bulletIndent1"><span class="glyph">●</span>80 months with mesangioproliferative/sclerosing disease</p><p class="bulletIndent1"><span class="glyph">●</span>87 months with membranous glomerulonephritis</p><p></p><p>Similar findings were noted in another single-center series of 66 patients with fibrillary glomerulonephritis, including a shorter time to ESKD in patients with membranoproliferative glomerulonephritis compared with mesangial proliferative/sclerosing disease [<a href="#rid4">4</a>]. However, the distinction between mesangioproliferative and membranoproliferative glomerulonephritis is likely related to the timing of the kidney biopsy rather than differences in pathogenesis, with mesangial proliferation representing a lesion seen at an early stage during the pathogenic process and a membranoproliferative pattern of injury seen at a late stage of the process [<a href="#rid75">75</a>].</p><p>It has been suggested that the prognosis may be better in immunotactoid glomerulopathy than in fibrillary glomerulonephritis [<a href="#rid6">6,35</a>]. However, a study that combined the clinical characteristics of 25 patients evaluated at one center with those of 161 patients described in various studies published between 1977 to 1994 found little, if any, difference in clinical outcomes in these two disorders (<a class="graphic graphic_table graphicRef54858" href="/z/d/graphic/54858.html" rel="external">table 1</a>) [<a href="#rid5">5,69</a>]. A case of spontaneous remission of immunotactoid glomerulopathy has been described [<a href="#rid76">76</a>]. (See <a class="local">'Clinical features'</a> above.)</p><p class="headingAnchor" id="H11"><span class="h1">OTHER FIBRILLARY DISORDERS</span><span class="headingEndMark"> — </span>Unlike fibrillary glomerulonephritis and immunotactoid glomerulopathy, other nonamyloid fibrillary glomerular diseases have been described in which staining for immunoglobulins is negative.</p><p class="headingAnchor" id="H12"><span class="h2">Fibronectin glomerulopathy</span><span class="headingEndMark"> — </span>Fibronectin glomerulopathy is an autosomal dominant disorder associated with massive deposition of fibronectin. It presents with proteinuria, often in the nephrotic range, in the third to fourth decade and slowly progresses to end-stage kidney disease (ESKD). Fibronectin glomerulopathy may recur after kidney transplantation [<a href="#rid77">77</a>]. (See  <a class="medical medical_review" href="/z/d/html/3072.html" rel="external">"Glomerulopathy with fibronectin deposits"</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Collagenofibrotic glomerulopathy</span><span class="headingEndMark"> — </span>Collagenofibrotic glomerulopathy, also called collagen type III glomerulopathy, is a rare disorder that is characterized by the massive accumulation of atypical type III collagen fibrils in the mesangium and subendothelial space (<a class="graphic graphic_picture graphicRef86281" href="/z/d/graphic/86281.html" rel="external">picture 6</a>) [<a href="#rid78">78,79</a>]. Light microscopy reveals findings consistent with membranoproliferative glomerulonephritis, including a double-contour appearance of the peripheral capillary walls. A definitive diagnosis requires electron microscopy, which reveals fibers with a transverse band structure and a distinctive periodicity of approximately 60 nm [<a href="#rid78">78</a>]. This is the same as that observed with type III collagen.</p><p>Controversy exists as to whether collagenofibrotic glomerulopathy is a primary disease of the kidney or a systemic process. Marked elevations in serum type III procollagen peptide levels are observed [<a href="#rid78">78</a>]. Some cases have been described in families, suggesting an autosomal recessive disorder [<a href="#rid78">78</a>].</p><p>Affected patients typically present with proteinuria and edema, with frequent progression to ESKD [<a href="#rid78">78</a>]. There is no specific therapy.</p><p class="headingAnchor" id="H14"><span class="h2">Other</span><span class="headingEndMark"> — </span>Patients with nail-patella syndrome and hereditary multiple exostoses syndrome (also called hereditary multiple osteochondromas syndrome) may develop nephrotic syndrome associated with glomerular fibrillar collagen deposition [<a href="#rid80">80</a>]. (See  <a class="medical medical_review" href="/z/d/html/6116.html" rel="external">"Nail-patella syndrome", section on 'Kidney manifestations'</a> and  <a class="medical medical_review" href="/z/d/html/7724.html" rel="external">"Chondrosarcoma", section on 'Secondary peripheral chondrosarcoma'</a>.)</p><p>Fibrils can also be seen in patients with diabetic glomerulosclerosis, a rare condition known as diabetic fibrillosis [<a href="#rid81">81</a>]. Within the kidney, these fibrils are localized to the mesangium, are segmental in fashion, and are bundle-like and not randomly arranged. Immunofluorescence staining for DnaJ heat shock protein family (Hsp40) member B9 (DNAJB9) is negative.</p><p class="headingAnchor" id="H3230786209"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110250.html" rel="external">"Society guideline links: Glomerular disease in adults"</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong> – Glomerular disease may be associated with the appearance of fibrillar deposits in the mesangium or glomerular basement membrane. The fibrils are Congo red positive in amyloidosis and are typically Congo red negative in other forms. The most common forms of nonamyloid fibrillary glomerular deposition diseases are fibrillary glomerulonephritis and immunotactoid glomerulopathy. Both disorders probably result from deposits derived from immunoglobulins. Cases of Congo red-positive fibrillary glomerulonephritis have been reported. Other forms of nonamyloid fibrillary deposition disease have been described in which the deposits are composed of fibronectin (fibronectin glomerulopathy) or atypical type III collagen fibrils (collagenofibrotic glomerulopathy). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – Fibrillary glomerulonephritis and immunotactoid glomerulopathy are uncommon but distinct disorders. The identification of the protein DnaJ heat shock protein family (Hsp40) member B9 (DNAJB9) in the glomeruli of patients with fibrillary glomerulonephritis but not in those with immunotactoid glomerulopathy has made it clear that the two are distinct, pathogenically unrelated disease entities. (See <a class="local">'Pathology and pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Patients with both fibrillary and immunotactoid disease present with significant proteinuria that is often in the nephrotic range; other findings include microscopic hematuria, hypertension, and kidney function impairment that may progress rapidly. Approximately one-half of the patients with fibrillary glomerulonephritis develop end-stage kidney disease (ESKD) within two to six years. Most cases of fibrillary glomerulonephritis and immunotactoid glomerulopathy are idiopathic. However, fibrillary glomerulonephritis has been associated with malignancy, monoclonal gammopathy, autoimmune disease, or infection in 30 to 50 percent of cases. Up to 40 percent of cases of immunotactoid glomerulopathy are associated with a B cell or plasma cell lymphoproliferative disorder. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of fibrillary glomerulonephritis or immunotactoid glomerulopathy is made by kidney biopsy in a patient with suspected glomerular disease. Fibrillary glomerulonephritis can be distinguished from immunotactoid glomerulopathy on the basis of electron microscopy as well as positive immunofluorescence staining for DNAJB9. Patients with a diagnosis of either fibrillary glomerulonephritis or immunotactoid glomerulopathy should be screened for malignancy, monoclonal gammopathy, autoimmune disease, and viral infections such as hepatitis C virus (HCV) and HIV. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Fibrillary and immunotactoid glomerular disease are difficult to treat and there are no randomized controlled trials to guide optimal therapy. Although we consider these disorders to be two pathologically distinct processes, our approach to treatment in patients with no secondary cause is similar for both and is based primarily upon the limited available data from retrospective studies and case series and our own clinical experience. There are <strong>no </strong>therapies that have been clearly shown to be beneficial for either idiopathic fibrillary glomerulonephritis or immunotactoid glomerulopathy. Patients with fibrillary glomerulonephritis who have a possible secondary cause for these disorders, such as malignancy, monoclonal gammopathy, infection, or autoimmune disease, may benefit from treatment of the underlying disorder. In patients with idiopathic fibrillary glomerulonephritis or immunotactoid glomerulopathy, our approach to treatment is generally determined by the severity of kidney dysfunction (see <a class="local">'Our approach to therapy'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with an estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m<sup>2</sup> <strong>and</strong> proteinuria &lt;3.5 g/day, we suggest a conservative initial approach to treatment. We treat these patients with antiproteinuric therapy (angiotensin-converting enzyme [ACE] inhibitors or angiotensin receptor blockers [ARBs]), blood pressure control, and dietary sodium restriction indefinitely. (See <a class="local">'Estimated GFR ≥60 mL/min/1.73 m2 and proteinuria &lt;3.5 g/day'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with an eGFR &lt;60 mL/min/1.73 m<sup>2</sup> <strong>or </strong>proteinuria &gt;3.5 g/day, we suggest treatment with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> in addition to conservative measures used to control blood pressure and reduce protein excretion (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We typically administer rituximab as four weekly doses of 375 mg/m<sup>2</sup> intravenously (IV) or as 1 g IV initially followed 14 days later by another 1 g dose. (See <a class="local">'Estimated GFR &lt;60 mL/min/1.73 m2 or proteinuria &gt;3.5 g/day'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients presenting with a rapidly progressive glomerulonephritis and crescents on kidney biopsy, we suggest treatment with high-dose glucocorticoids and <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> as used in other forms of crescentic glomerulonephritis. (See <a class="local">'Patients with crescentic glomerulonephritis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>End-stage kidney disease</strong> – Dialysis or kidney transplantation can be performed in patients with fibrillary glomerulonephritis or immunotactoid glomerulopathy who progress to ESKD. With kidney transplantation, recurrent disease can develop in the allograft in both disorders, but the rate of progression is usually slower than in the native kidney. The rate of recurrence appears to be higher in patients who have a monoclonal gammopathy. (See <a class="local">'End-stage kidney disease'</a> above.)</p><p></p><p class="headingAnchor" id="H301434651"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Gerald B Appel, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Alpers CE, Rennke HG, Hopper J Jr, Biava CG. Fibrillary glomerulonephritis: an entity with unusual immunofluorescence features. Kidney Int 1987; 31:781.</a></li><li><a class="nounderline abstract_t">Iskandar SS, Falk RJ, Jennette JC. Clinical and pathologic features of fibrillary glomerulonephritis. Kidney Int 1992; 42:1401.</a></li><li><a class="nounderline abstract_t">Rosenstock JL, Markowitz GS, Valeri AM, et al. Fibrillary and immunotactoid glomerulonephritis: Distinct entities with different clinical and pathologic features. Kidney Int 2003; 63:1450.</a></li><li><a class="nounderline abstract_t">Nasr SH, Valeri AM, Cornell LD, et al. Fibrillary glomerulonephritis: a report of 66 cases from a single institution. Clin J Am Soc Nephrol 2011; 6:775.</a></li><li><a class="nounderline abstract_t">Pronovost PH, Brady HR, Gunning ME, et al. Clinical features, predictors of disease progression and results of renal transplantation in fibrillary/immunotactoid glomerulopathy. Nephrol Dial Transplant 1996; 11:837.</a></li><li><a class="nounderline abstract_t">Fogo A, Qureshi N, Horn RG. Morphologic and clinical features of fibrillary glomerulonephritis versus immunotactoid glomerulopathy. Am J Kidney Dis 1993; 22:367.</a></li><li><a class="nounderline abstract_t">Nasr SH, Fogo AB. New developments in the diagnosis of fibrillary glomerulonephritis. Kidney Int 2019; 96:581.</a></li><li><a class="nounderline abstract_t">Korbet SM, Schwartz MM, Lewis EJ. Immunotactoid glomerulopathy. Am J Kidney Dis 1991; 17:247.</a></li><li><a class="nounderline abstract_t">Alpers CE. Immunotactoid (microtubular) glomerulopathy: an entity distinct from fibrillary glomerulonephritis? Am J Kidney Dis 1992; 19:185.</a></li><li><a class="nounderline abstract_t">Schwartz MM, Korbet SM, Lewis EJ. Immunotactoid glomerulopathy. J Am Soc Nephrol 2002; 13:1390.</a></li><li><a class="nounderline abstract_t">Bridoux F, Hugue V, Coldefy O, et al. Fibrillary glomerulonephritis and immunotactoid (microtubular) glomerulopathy are associated with distinct immunologic features. Kidney Int 2002; 62:1764.</a></li><li><a class="nounderline abstract_t">Nickeleit V, Moll S, Schmid M, Mihatsch MJ. Nephrotic syndrome in an adult: the ongoing saga of fibrils versus microtubules. Am J Kidney Dis 1999; 34:1146.</a></li><li><a class="nounderline abstract_t">Dasari S, Alexander MP, Vrana JA, et al. DnaJ Heat Shock Protein Family B Member 9 Is a Novel Biomarker for Fibrillary GN. J Am Soc Nephrol 2018; 29:51.</a></li><li><a class="nounderline abstract_t">Andeen NK, Yang HY, Dai DF, et al. DnaJ Homolog Subfamily B Member 9 Is a Putative Autoantigen in Fibrillary GN. J Am Soc Nephrol 2018; 29:231.</a></li><li><a class="nounderline abstract_t">Nasr SH, Vrana JA, Dasari S, et al. DNAJB9 Is a Specific Immunohistochemical Marker for Fibrillary Glomerulonephritis. Kidney Int Rep 2018; 3:56.</a></li><li><a class="nounderline abstract_t">El-Husseini A, Aycinena JC, George B, et al. Fibrillary glomerulonephritis masquerading as rapidly progressive glomerulonephritis with pseudo-linear glomerular basement membrane staining. Clin Nephrol 2015; 84:231.</a></li><li><a class="nounderline abstract_t">Yang GC, Nieto R, Stachura I, Gallo GR. Ultrastructural immunohistochemical localization of polyclonal IgG, C3, and amyloid P component on the congo red-negative amyloid-like fibrils of fibrillary glomerulopathy. Am J Pathol 1992; 141:409.</a></li><li><a class="nounderline abstract_t">Thomas JA, Vasin D, Lin M, et al. A case of mistaken identity: fibrillary glomerulonephritis masquerading as crescentic anti-glomerular basement membrane disease. Clin Nephrol 2016; 85:114.</a></li><li><a class="nounderline abstract_t">Javaugue V, Karras A, Glowacki F, et al. Long-term kidney disease outcomes in fibrillary glomerulonephritis: a case series of 27 patients. Am J Kidney Dis 2013; 62:679.</a></li><li><a class="nounderline abstract_t">Said SM, Rocha AB, Royal V, et al. Immunoglobulin-Negative DNAJB9-Associated Fibrillary Glomerulonephritis: A Report of 9 Cases. Am J Kidney Dis 2021; 77:454.</a></li><li><a class="nounderline abstract_t">Said SM, Leung N, Alexander MP, et al. DNAJB9-positive monotypic fibrillary glomerulonephritis is not associated with monoclonal gammopathy in the vast majority of patients. Kidney Int 2020; 98:498.</a></li><li><a class="nounderline abstract_t">Nasr SH, Fidler ME, Said SM, et al. Immunofluorescence staining for immunoglobulin heavy chain/light chain on kidney biopsies is a valuable ancillary technique for the diagnosis of monoclonal gammopathy-associated kidney diseases. Kidney Int 2021; 100:155.</a></li><li><a class="nounderline abstract_t">Alexander MP, Dasari S, Vrana JA, et al. Congophilic Fibrillary Glomerulonephritis: A Case Series. Am J Kidney Dis 2018; 72:325.</a></li><li><a class="nounderline abstract_t">Markowitz GS, Cheng JT, Colvin RB, et al. Hepatitis C viral infection is associated with fibrillary glomerulonephritis and immunotactoid glomerulopathy. J Am Soc Nephrol 1998; 9:2244.</a></li><li><a class="nounderline abstract_t">Behnke J, Mann MJ, Scruggs FL, et al. Members of the Hsp70 Family Recognize Distinct Types of Sequences to Execute ER Quality Control. Mol Cell 2016; 63:739.</a></li><li><a class="nounderline abstract_t">Sethi S, Palma LMP, Theis JD, Fervenza FC. Proteomic Analysis of Complement Proteins in Glomerular Diseases. Kidney Int Rep 2023; 8:827.</a></li><li><a class="nounderline abstract_t">Watanabe K, Nakai K, Hosokawa N, et al. A Case of Fibrillary Glomerulonephritis with Fibril Deposition in the Arteriolar Wall and a Family History of Renal Disease. Case Rep Nephrol Dial 2017; :26.</a></li><li><a class="nounderline abstract_t">Chan TM, Chan KW. Fibrillary glomerulonephritis in siblings. Am J Kidney Dis 1998; 31:E4.</a></li><li><a class="nounderline abstract_t">Ying T, Hill P, Desmond M, et al. Fibrillary glomerulonephritis: An apparent familial form? Nephrology (Carlton) 2015; 20:506.</a></li><li><a class="nounderline abstract_t">Andeen NK, Troxell ML, Riazy M, et al. Fibrillary Glomerulonephritis: Clinicopathologic Features and Atypical Cases from a Multi-Institutional Cohort. Clin J Am Soc Nephrol 2019; 14:1741.</a></li><li><a class="nounderline abstract_t">Nasr SH, Kudose SS, Said SM, et al. Immunotactoid glomerulopathy is a rare entity with monoclonal and polyclonal variants. Kidney Int 2021; 99:410.</a></li><li><a class="nounderline abstract_t">Inotani S, Horino T, Ishihara M, et al. Immunotactoid glomerulopathy associated with monoclonal gammopathy. Lancet 2021; 397:2081.</a></li><li><a class="nounderline abstract_t">Javaugue V, Dufour-Nourigat L, Desport E, et al. Results of a nation-wide cohort study suggest favorable long-term outcomes of clone-targeted chemotherapy in immunotactoid glomerulopathy. Kidney Int 2021; 99:421.</a></li><li><a class="nounderline abstract_t">Bu L, Javaugue V, Chauvet S, et al. Light Chain-Only Immunotactoid Glomerulopathy: A Case Report. Am J Kidney Dis 2023; 81:611.</a></li><li><a class="nounderline abstract_t">Nasr SH, Fidler ME, Cornell LD, et al. Immunotactoid glomerulopathy: clinicopathologic and proteomic study. Nephrol Dial Transplant 2012; 27:4137.</a></li><li><a class="nounderline abstract_t">Payan Schober F, Jobson MA, Poulton CJ, et al. Clinical Features and Outcomes of a Racially Diverse Population with Fibrillary Glomerulonephritis. Am J Nephrol 2017; 45:248.</a></li><li><a class="nounderline abstract_t">Moulin B, Ronco PM, Mougenot B, et al. Glomerulonephritis in chronic lymphocytic leukemia and related B-cell lymphomas. Kidney Int 1992; 42:127.</a></li><li><a class="nounderline abstract_t">Lodhi MU, Saleem TS, Usman MS, et al. Fibrillary Glomerulonephritis in a Patient with Sjogren's Syndrome. Cureus 2018; 10:e2483.</a></li><li><a class="nounderline abstract_t">Sehgal R, Sajjad SM, Thapa JK. Fibrillary Glomerulonephritis in Primary Sjogren's Syndrome: A Rare Cause of Renal Failure. Clin Med Res 2017; 15:100.</a></li><li><a class="nounderline abstract_t">Yun YS, Song HC, Lee K, et al. Fibrillary glomerulonephritis in rheumatoid arthritis. Nephrology (Carlton) 2010; 15:266.</a></li><li><a class="nounderline abstract_t">Kim HJ, Kang SW, Park SJ, et al. Fibrillary glomerulonephritis associated with Behçet's syndrome. Ren Fail 2012; 34:637.</a></li><li><a class="nounderline abstract_t">DiFranza LT, Chafouleas E, Katipally S, et al. Crescentic Fibrillary Glomerulonephritis in the Setting of Immune Checkpoint Inhibitor Therapy: A Report of Two Cases. Glomerular Dis 2023; 3:69.</a></li><li><a class="nounderline abstract_t">Al-Sawalmeh K, Pandes M, Niño JA, Avila-Casado C. Acute kidney injury after Pfizer COVID-19 vaccine due to crescentic fibrillary glomerulonephritis. Clin Nephrol 2022; 98:205.</a></li><li><a class="nounderline abstract_t">Cheungpasitporn W, Zacharek CC, Fervenza FC, et al. Rapidly progressive glomerulonephritis due to coexistent anti-glomerular basement membrane disease and fibrillary glomerulonephritis. Clin Kidney J 2016; 9:97.</a></li><li><a class="nounderline abstract_t">Korbet SM, Rosenberg BF, Schwartz MM, Lewis EJ. Course of renal transplantation in immunotactoid glomerulopathy. Am J Med 1990; 89:91.</a></li><li><a class="nounderline abstract_t">Czarnecki PG, Lager DJ, Leung N, et al. Long-term outcome of kidney transplantation in patients with fibrillary glomerulonephritis or monoclonal gammopathy with fibrillary deposits. Kidney Int 2009; 75:420.</a></li><li><a class="nounderline abstract_t">Masson RG, Rennke HG, Gottlieb MN. Pulmonary hemorrhage in a patient with fibrillary glomerulonephritis. N Engl J Med 1992; 326:36.</a></li><li><a class="nounderline abstract_t">Magro CM, Calomeni EP, Nadasdy T, et al. Ultrastructure as a diagnostic adjunct in the evaluation of lung allograft biopsies. Ultrastruct Pathol 2005; 29:95.</a></li><li><a class="nounderline abstract_t">Satoskar AA, Calomeni E, Nadasdy G, et al. Fibrillary glomerulonephritis with splenic involvement: a detailed autopsy study. Ultrastruct Pathol 2008; 32:113.</a></li><li><a class="nounderline abstract_t">Wallner M, Prischl FC, Höbling W, et al. Immunotactoid glomerulopathy with extrarenal deposits in the bone, and chronic cholestatic liver disease. Nephrol Dial Transplant 1996; 11:1619.</a></li><li><a class="nounderline abstract_t">Da'as N, Kleinman Y, Polliack A, et al. Immunotactoid glomerulopathy with massive bone marrow deposits in a patient with IgM kappa monoclonal gammopathy and hypocomplementemia. Am J Kidney Dis 2001; 38:395.</a></li><li><a class="nounderline abstract_t">Schifferli JA, Merot Y, Cruchaud A, Chatelanat F. Immunotactoid glomerulopathy with leucocytoclastic skin vasculitis and hypocomplementemia: a case report. Clin Nephrol 1987; 27:151.</a></li><li><a class="nounderline abstract_t">Nasr SH, Dasari S, Lieske JC, et al. Serum levels of DNAJB9 are elevated in fibrillary glomerulonephritis patients. Kidney Int 2019; 95:1269.</a></li><li><a class="nounderline abstract_t">Bjørneklett R, Vikse BE, Svarstad E, et al. Long-term risk of cancer in membranous nephropathy patients. Am J Kidney Dis 2007; 50:396.</a></li><li><a class="nounderline abstract_t">Fermand JP, Bridoux F, Kyle RA, et al. How I treat monoclonal gammopathy of renal significance (MGRS). Blood 2013; 122:3583.</a></li><li><a class="nounderline abstract_t">Hogan JJ, Vogl DT. Untangling immunotactoid glomerulopathy in the MGRS era. Kidney Int 2021; 99:303.</a></li><li><a class="nounderline abstract_t">Zand L, Rajkumar SV, Leung N, et al. Safety and Efficacy of Daratumumab in Patients with Proliferative GN with Monoclonal Immunoglobulin Deposits. J Am Soc Nephrol 2021; 32:1163.</a></li><li><a class="nounderline abstract_t">Quattrocchio G, Barreca A, Vaccarino A, et al. Monoclonal Gammopathy of Renal Significance: Clinical and Histological Efficacy of a Bortezomib-Based Regimen. Front Med (Lausanne) 2020; 7:587345.</a></li><li><a class="nounderline abstract_t">Bhat P, Weiss S, Appel GB, Radhakrishnan J. Rituximab treatment of dysproteinemias affecting the kidney: a review of three cases. Am J Kidney Dis 2007; 50:641.</a></li><li><a class="nounderline abstract_t">Vilayur E, Trevillian P, Walsh M. Monoclonal gammopathy and glomerulopathy associated with chronic lymphocytic leukemia. Nat Clin Pract Nephrol 2009; 5:54.</a></li><li><a class="nounderline abstract_t">Collins M, Navaneethan SD, Chung M, et al. Rituximab treatment of fibrillary glomerulonephritis. Am J Kidney Dis 2008; 52:1158.</a></li><li><a class="nounderline abstract_t">Hogan J, Restivo M, Canetta PA, et al. Rituximab treatment for fibrillary glomerulonephritis. Nephrol Dial Transplant 2014; 29:1925.</a></li><li><a class="nounderline abstract_t">Erickson SB, Zand L, Nasr SH, et al. Treatment of fibrillary glomerulonephritis with rituximab: a 12-month pilot study. Nephrol Dial Transplant 2021; 36:104.</a></li><li><a class="nounderline abstract_t">Carles X, Rostaing L, Modesto A, et al. Successful treatment of recurrence of immunotactoid glomerulopathy in a kidney allograft recipient. Nephrol Dial Transplant 2000; 15:897.</a></li><li><a class="nounderline abstract_t">D'Agati V, Sacchi G, Truong L, et al. Fibrillary glomerulopathy: Defining the disease spectrum [abstract]. J Am Soc Nephrol 1991; 2:591.</a></li><li><a class="nounderline abstract_t">Mahajan S, Kalra V, Dinda AK, et al. Fibrillary glomerulonephritis presenting as rapidly progressive renal failure in a young female: a case report. Int Urol Nephrol 2005; 37:561.</a></li><li><a class="nounderline abstract_t">Sharma P, Kuperman M, Racusen L, Geetha D. Fibrillary glomerulonephritis presenting as rapidly progressive glomerulonephritis. Am J Kidney Dis 2012; 60:157.</a></li><li><a class="nounderline abstract_t">Javaugue V, Said SM, Bu L, et al. Prognostic Value of Diffuse Crescentic Lesions in Fibrillary Glomerulonephritis. Am J Kidney Dis 2023; 81:368.</a></li><li><a class="nounderline abstract_t">Brady HR. Fibrillary glomerulopathy. Kidney Int 1998; 53:1421.</a></li><li><a class="nounderline abstract_t">Marin JM, Agusti A, Villar I, et al. Association between treated and untreated obstructive sleep apnea and risk of hypertension. JAMA 2012; 307:2169.</a></li><li><a class="nounderline abstract_t">El Ters M, Bobart SA, Cornell LD, et al. Recurrence of DNAJB9-Positive Fibrillary Glomerulonephritis After Kidney Transplantation: A Case Series. Am J Kidney Dis 2020; 76:500.</a></li><li><a class="nounderline abstract_t">Mallett A, Tang W, Hart G, et al. End-Stage Kidney Disease Due to Fibrillary Glomerulonephritis and Immunotactoid Glomerulopathy - Outcomes in 66 Consecutive ANZDATA Registry Cases. Am J Nephrol 2015; 42:177.</a></li><li><a class="nounderline abstract_t">Sathyan S, Khan FN, Ranga KV. A case of recurrent immunotactoid glomerulopathy in an allograft treated with rituximab. Transplant Proc 2009; 41:3953.</a></li><li><a class="nounderline abstract_t">Jeyabalan A, Batal I, Piras D, et al. Familial Fibrillary Glomerulonephritis in Living Related Kidney Transplantation. Kidney Int Rep 2021; 6:239.</a></li><li><a class="nounderline abstract_t">Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification. Semin Nephrol 2011; 31:341.</a></li><li><a class="nounderline abstract_t">Rood IM, Lieverse LG, Steenbergen EJ, et al. Spontaneous remission of immunotactoid glomerulopathy. Neth J Med 2011; 69:341.</a></li><li><a class="nounderline abstract_t">Otsuka Y, Takeda A, Horike K, et al. A recurrent fibronectin glomerulopathy in a renal transplant patient: a case report. Clin Transplant 2012; 26 Suppl 24:58.</a></li><li><a class="nounderline abstract_t">Alchi B, Nishi S, Narita I, Gejyo F. Collagenofibrotic glomerulopathy: clinicopathologic overview of a rare glomerular disease. Am J Kidney Dis 2007; 49:499.</a></li><li><a class="nounderline abstract_t">Chen N, Pan X, Xu Y, et al. Two brothers in one Chinese family with collagen type III glomerulopathy. Am J Kidney Dis 2007; 50:1037.</a></li><li><a class="nounderline abstract_t">Roberts IS, Gleadle JM. Familial nephropathy and multiple exostoses with exostosin-1 (EXT1) gene mutation. J Am Soc Nephrol 2008; 19:450.</a></li><li><a class="nounderline abstract_t">Sohar E, Ravid M, Ben-Shaul Y, et al. Diabetic fibrillosis. A report of three cases. Am J Med 1970; 49:64.</a></li></ol></div><div id="topicVersionRevision">Topic 3115 Version 34.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3106698" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Fibrillary glomerulonephritis: an entity with unusual immunofluorescence features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1474772" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Clinical and pathologic features of fibrillary glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12631361" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Fibrillary and immunotactoid glomerulonephritis: Distinct entities with different clinical and pathologic features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21441134" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Fibrillary glomerulonephritis: a report of 66 cases from a single institution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8671905" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Clinical features, predictors of disease progression and results of renal transplantation in fibrillary/immunotactoid glomerulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8372831" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Morphologic and clinical features of fibrillary glomerulonephritis versus immunotactoid glomerulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31227146" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : New developments in the diagnosis of fibrillary glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1996564" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Immunotactoid glomerulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1739104" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Immunotactoid (microtubular) glomerulopathy: an entity distinct from fibrillary glomerulonephritis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11961029" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Immunotactoid glomerulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12371978" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Fibrillary glomerulonephritis and immunotactoid (microtubular) glomerulopathy are associated with distinct immunologic features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10585329" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Nephrotic syndrome in an adult: the ongoing saga of fibrils versus microtubules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29097623" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : DnaJ Heat Shock Protein Family B Member 9 Is a Novel Biomarker for Fibrillary GN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29097624" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : DnaJ Homolog Subfamily B Member 9 Is a Putative Autoantigen in Fibrillary GN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29340314" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : DNAJB9 Is a Specific Immunohistochemical Marker for Fibrillary Glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26249548" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Fibrillary glomerulonephritis masquerading as rapidly progressive glomerulonephritis with pseudo-linear glomerular basement membrane staining.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1497092" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Ultrastructural immunohistochemical localization of polyclonal IgG, C3, and amyloid P component on the congo red-negative amyloid-like fibrils of fibrillary glomerulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26636330" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A case of mistaken identity: fibrillary glomerulonephritis masquerading as crescentic anti-glomerular basement membrane disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23759297" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Long-term kidney disease outcomes in fibrillary glomerulonephritis: a case series of 27 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32711071" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Immunoglobulin-Negative DNAJB9-Associated Fibrillary Glomerulonephritis: A Report of 9 Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32622524" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : DNAJB9-positive monotypic fibrillary glomerulonephritis is not associated with monoclonal gammopathy in the vast majority of patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33774084" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Immunofluorescence staining for immunoglobulin heavy chain/light chain on kidney biopsies is a valuable ancillary technique for the diagnosis of monoclonal gammopathy-associated kidney diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29866458" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Congophilic Fibrillary Glomerulonephritis: A Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9848778" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Hepatitis C viral infection is associated with fibrillary glomerulonephritis and immunotactoid glomerulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27546788" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Members of the Hsp70 Family Recognize Distinct Types of Sequences to Execute ER Quality Control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37069992" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Proteomic Analysis of Complement Proteins in Glomerular Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28503551" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A Case of Fibrillary Glomerulonephritis with Fibril Deposition in the Arteriolar Wall and a Family History of Renal Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10074581" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Fibrillary glomerulonephritis in siblings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26063488" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Fibrillary glomerulonephritis: An apparent familial form?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31685544" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Fibrillary Glomerulonephritis: Clinicopathologic Features and Atypical Cases from a Multi-Institutional Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32818517" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Immunotactoid glomerulopathy is a rare entity with monoclonal and polyclonal variants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34062142" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Immunotactoid glomerulopathy associated with monoclonal gammopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32739419" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Results of a nation-wide cohort study suggest favorable long-term outcomes of clone-targeted chemotherapy in immunotactoid glomerulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36328099" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Light Chain-Only Immunotactoid Glomerulopathy: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22872726" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Immunotactoid glomerulopathy: clinicopathologic and proteomic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28161700" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Clinical Features and Outcomes of a Racially Diverse Population with Fibrillary Glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1635342" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Glomerulonephritis in chronic lymphocytic leukemia and related B-cell lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29922524" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Fibrillary Glomerulonephritis in a Patient with Sjogren's Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29196420" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Fibrillary Glomerulonephritis in Primary Sjogren's Syndrome: A Rare Cause of Renal Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20470291" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Fibrillary glomerulonephritis in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22417126" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Fibrillary glomerulonephritis associated with Behçet's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37113492" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Crescentic Fibrillary Glomerulonephritis in the Setting of Immune Checkpoint Inhibitor Therapy: A Report of Two Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35900077" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Acute kidney injury after Pfizer COVID-19 vaccine due to crescentic fibrillary glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26798468" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Rapidly progressive glomerulonephritis due to coexistent anti-glomerular basement membrane disease and fibrillary glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2368797" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Course of renal transplantation in immunotactoid glomerulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19037251" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Long-term outcome of kidney transplantation in patients with fibrillary glomerulonephritis or monoclonal gammopathy with fibrillary deposits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1727064" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Pulmonary hemorrhage in a patient with fibrillary glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16028666" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Ultrastructure as a diagnostic adjunct in the evaluation of lung allograft biopsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18570157" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Fibrillary glomerulonephritis with splenic involvement: a detailed autopsy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8856222" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Immunotactoid glomerulopathy with extrarenal deposits in the bone, and chronic cholestatic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11479168" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Immunotactoid glomerulopathy with massive bone marrow deposits in a patient with IgM kappa monoclonal gammopathy and hypocomplementemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3552344" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Immunotactoid glomerulopathy with leucocytoclastic skin vasculitis and hypocomplementemia: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31010480" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Serum levels of DNAJB9 are elevated in fibrillary glomerulonephritis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17720518" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Long-term risk of cancer in membranous nephropathy patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24108460" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : How I treat monoclonal gammopathy of renal significance (MGRS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33509349" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Untangling immunotactoid glomerulopathy in the MGRS era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33685975" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Safety and Efficacy of Daratumumab in Patients with Proliferative GN with Monoclonal Immunoglobulin Deposits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33392216" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Monoclonal Gammopathy of Renal Significance: Clinical and Histological Efficacy of a Bortezomib-Based Regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17900464" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Rituximab treatment of dysproteinemias affecting the kidney: a review of three cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19030000" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Monoclonal gammopathy and glomerulopathy associated with chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18823685" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Rituximab treatment of fibrillary glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24867652" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Rituximab treatment for fibrillary glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32617582" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Treatment of fibrillary glomerulonephritis with rituximab: a 12-month pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10831649" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Successful treatment of recurrence of immunotactoid glomerulopathy in a kidney allograft recipient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Fibrillary glomerulopathy: Defining the disease spectrum [abstract]</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16307342" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Fibrillary glomerulonephritis presenting as rapidly progressive renal failure in a young female: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22398109" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Fibrillary glomerulonephritis presenting as rapidly progressive glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36228825" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Prognostic Value of Diffuse Crescentic Lesions in Fibrillary Glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9573563" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Fibrillary glomerulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22618924" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Association between treated and untreated obstructive sleep apnea and risk of hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32414663" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Recurrence of DNAJB9-Positive Fibrillary Glomerulonephritis After Kidney Transplantation: A Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26418732" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : End-Stage Kidney Disease Due to Fibrillary Glomerulonephritis and Immunotactoid Glomerulopathy - Outcomes in 66 Consecutive ANZDATA Registry Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19917422" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : A case of recurrent immunotactoid glomerulopathy in an allograft treated with rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33426405" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Familial Fibrillary Glomerulonephritis in Living Related Kidney Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21839367" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21934180" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Spontaneous remission of immunotactoid glomerulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22747478" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : A recurrent fibronectin glomerulopathy in a renal transplant patient: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17386317" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Collagenofibrotic glomerulopathy: clinicopathologic overview of a rare glomerular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18037106" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Two brothers in one Chinese family with collagen type III glomerulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18216313" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Familial nephropathy and multiple exostoses with exostosin-1 (EXT1) gene mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5431478" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Diabetic fibrillosis. A report of three cases.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
